US 12,458,950 B2
Adsorbent and a kit containing said adsorbent in a column
Kurt Nilsson, Trelleborg (SE)
Assigned to GLYCOPROBE AB, Lund (SE)
Appl. No. 17/772,427
Filed by GLYCOPROBE AB, Lund (SE)
PCT Filed Oct. 29, 2020, PCT No. PCT/SE2020/051051
§ 371(c)(1), (2) Date Apr. 27, 2022,
PCT Pub. No. WO2021/086259, PCT Pub. Date May 6, 2021.
Claims priority of application No. 1900180-9 (SE), filed on Oct. 30, 2019.
Prior Publication US 2023/0302429 A1, Sep. 28, 2023
Int. Cl. B01J 20/24 (2006.01); A61L 2/06 (2006.01); B01J 20/28 (2006.01); B01J 20/289 (2006.01)
CPC B01J 20/24 (2013.01) [A61L 2/06 (2013.01); B01J 20/28016 (2013.01); B01J 20/28052 (2013.01); B01J 20/289 (2013.01); B01J 2220/54 (2013.01)] 11 Claims
 
1. An adsorbent comprising at least two types of covalently bound antigens having the ability to bind at least one component present in a blood flow or blood plasma flow passing through said adsorbent, wherein said at least two types of antigen comprises at least one linear peptide and at least one cyclic peptide, and optionally at least one protein,
wherein optionally a spacer is provided between the peptide and the adsorbent,
wherein said at least one linear peptide is at least one linear citrullinated peptide and wherein said at least one cyclic peptide is at least one cyclic citrullinated peptide, wherein said at least one cyclic citrullinated peptide is derived from a peptide sequence having the ability to bind to certain autoantibodies found in blood from patients with rheumatoid arthritis (RA), wherein said peptide sequence is derived from a protein selected from filaggrin, fibrin, fibrinogen, vimentin, and enolase.